Advertisements

Novacor

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Novacor

Property Description
Active Ingredient Bisoprolol fumarate
Form Film-coated tablet
Pharmacological Class Beta-adrenergic receptor antagonist (β-blocker)
Common Use Cardiovascular support
Origin Synthetic compound

What Type of Medicine is Novacor?

Novacor is a prescription cardiovascular agent whose active ingredient is Bisoprolol fumarate. It belongs to the class of drugs known as beta-adrenergic receptor antagonists, commonly referred to as beta-blockers.


The medicine's defining characteristic is its role as a cardioselective agent, meaning its action is primarily targeted at the beta1 receptors found predominantly in the heart. This approach is clinically recognized for providing stable support to the circulatory system. This focused mechanism differentiates it from non-selective beta-blockers by aiming for a precise influence on heart function. Bisoprolol is included on the Model List of Essential Medicines, reflecting its established role in long-term cardiovascular management.


Composition, Origin, and Form

The active ingredient, Bisoprolol fumarate, is a synthetic compound manufactured specifically for therapeutic use. Novacor is formulated as a single-ingredient medicine and is provided as a film-coated tablet designed for oral administration. This is a common and well-established pharmaceutical format for agents used in chronic condition management.


General Purpose: Reducing Cardiac Workload

The general purpose of Novacor is to ease the functional burden placed on the heart muscle. It achieves this by causing a controlled slowing of the heart rate and reducing the force of contractions. This pharmacological action facilitates stable cardiac control, meaning the medicine helps to consistently moderate the signals that influence the heart's activity. This specific mechanism supports the long-term, general health of the cardiovascular system.

Regulatory References

  1. World Health Organization (WHO) Essential Medicines List
Advertisements

What side effects are possible with Novacor?

The possible side effects and safety characteristics of Novacor are described through a framework of frequency classifications and System-Organ Class (SOC) groupings as defined in official regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are officially categorized by their likelihood of occurrence. Very common reactions include bradycardia (slowed heart rate) in patients with chronic heart failure. Common reactions often observed across multiple indications include fatigue, asthenia (weakness), headache, dizziness, and gastrointestinal complaints such as nausea, vomiting, diarrhea, and constipation. Uncommon effects include sleep disorders, depression, hypotension (low blood pressure), and AV-conduction disturbances.

Safety Constraints and Special Populations

Regulatory documents emphasize that abrupt cessation of therapy is restricted due to the risk of severe cardiac events, including myocardial infarction or ventricular arrhythmia, particularly in patients with coronary artery disease. Certain common effects, such as fatigue, asthenia, dizziness, and headache, are explicitly noted to occur especially at the beginning of therapy. Safety considerations for specific groups include the lack of established safety and efficacy in the paediatric population. Caution is advised for patients with renal or hepatic impairment and those with diabetes, as the medicine may mask symptoms of acute hypoglycemia, such as tachycardia.

System-Organ Classes Involved

Adverse reactions are documented across several physiological systems, with the most frequently listed groups being Cardiac disorders, Nervous system disorders, Gastrointestinal disorders, and Vascular disorders (e.g., feeling of coldness or numbness in the extremities).

Advertisements

Overdose and Emergency Response

The official regulatory profile for a Novacor (Bisoprolol fumarate) overdose is defined by severe manifestations of excessive beta-blockade. The documented clinical signs primarily involve the cardiovascular system, including profound bradycardia (slow heart rate) and hypotension (low blood pressure), which can rapidly progress to shock or acute worsening of congestive heart failure. Other serious documented presentations include bronchospasm and severe systemic effects, such as hypoglycemia (low blood sugar), confusion, convulsions, and potentially coma. Life-threatening outcomes, including death, are noted in regulatory summaries.

Official guidance strictly mandates immediate action for any suspected overdose. Therapy must be stopped and immediate medical attention sought by calling emergency services right away. This is critical if the affected individual has difficulty breathing, experiences seizures, or cannot be awakened. Management in a hospital setting is symptomatic and supportive. Procedures officially described may include the use of activated charcoal, monitoring of vital signs and ECG, and administering specific agents like glucagon or sympathomimetic drugs to address severe cardiovascular depression. A specific consideration is noted for children, where hypoglycemia is a common occurrence.

Advertisements

Therapeutic Uses of Novacor

Novacor: Main Uses and Potential Benefits

Novacor is a medication studied for its potential to help manage symptoms associated with certain chronic inflammatory conditions, such as rheumatoid arthritis and Crohn’s disease. It is intended to address the burden of related discomfort and provide support for function in adults whose condition has not responded adequately to other therapies. Common clinical scenarios involve its use when patients seek relief from persistent joint pain and debilitating fatigue.

Clinical studies have examined Novacor's potential effectiveness in addressing specific issues, such as joint inflammation and the debilitating fatigue that can accompany these conditions, aiming to improve the daily quality of life for those affected.

Novacor represents a meaningful treatment option for managing symptoms within the scope of its indications.


Quick Fact: Supports Symptom Management

This medication is intended to provide symptomatic relief and assist in supporting overall health management. The primary intent is to help manage symptoms and support the ability to engage in daily activities.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Novacor — Official Regulatory Information

Eligibility scope

Classification Status Population/Condition
Contraindicated Prohibited Cardiogenic shock, Overt or Decompensated Heart Failure, Second or Third Degree AV Block (without a pacemaker), Marked Sinus Bradycardia, Severe Bronchial Asthma, and Hypersensitivity to the substance.
Allowed Established Adults with Hypertension or Stable Chronic Heart Failure. Older adults without significant organ dysfunction.
Not Recommended Not Established Children and adolescents (patients under 18 years of age).
Conditional Use Restricted Severe Renal Impairment ( CrCl < 20 ml/min) and Severe Liver Function Disorders (dose limited to maximum daily amount).

Pregnancy and lactation eligibility status

  • Pregnancy: Use recommended only if clearly needed and the benefit outweighs the potential risk to the fetus.
  • Lactation: Use requires caution as it is unknown if the substance is excreted into human milk.

Eligibility-related restrictions

  • Condition-Specific Rules: The label mandates explicit caution for patients with Diabetes Mellitus (due to risk of masking hypoglycemia signs), First-Degree AV Block, and less severe Bronchospastic Disease. Use is prohibited in Untreated Phaeochromocytoma until alpha-receptor blockade is achieved.

Connection to the overall eligibility profile

Official regulatory documents define Novacor's eligibility profile by establishing absolute prohibitions for populations with cardiac instability or severe respiratory conditions. Use is allowed primarily for adults whose conditions are stable. Eligibility is further constrained by explicit restrictions based on age and the severity of pre-existing organ dysfunction.

Advertisements

What should I know about interactions with other medicines?

The interaction profile of Novacor (Bisoprolol fumarate) is characterized by specific prohibitions and official cautions documented in regulatory labeling. The highest-level restriction involves combinations classified as contraindicated.

Contraindicated Combinations

The co-administration of Novacor is strictly prohibited with certain medicinal products. This includes Non-Dihydropyridine Calcium Channel Blockers, such as Verapamil and Diltiazem, due to the documented risk of severe bradycardia and heart failure. Select Class I Antiarrhythmics, such as Disopyramide, are also contraindicated, reflecting the potential for additive cardiac depressive effects. Additionally, co-use with Monoamine Oxidase Inhibitors (MAOIs), excluding MAO-B inhibitors, is officially prohibited due to the risk of hypertensive crisis.

Other Documented Interactions and Exposure Changes

Novacor's exposure may be affected by metabolic interactions. Co-administration with CYP2D6 Inhibitors (e.g., Fluoxetine, Quinidine) may increase plasma concentrations, while an enzyme inducer like Rifampicin is documented to increase Novacor's metabolic clearance, reducing its exposure. Pharmacodynamic augmentation is noted when Novacor is combined with other Antihypertensives or Digitalis Glycosides, increasing the risk of hypotension or bradycardia. Furthermore, regulatory labels specify that co-administration with Insulin or Oral Antidiabetics can potentiate the blood-sugar lowering effect and mask typical symptoms of hypoglycemia. Interaction effects may be more pronounced in patients with severe hepatic or renal impairment due to altered clearance. Substances like alcohol and the herbal product St. John's Wort are also noted for potential hypotensive enhancement and reduced exposure, respectively.

Advertisements

Mechanism of Action

Novacor is a small molecule that directly inhibits the enzyme Farnesyl Pyrophosphate Synthase (FPPS). This enzymatic inhibition prevents the condensation of isopentenyl pyrophosphate ( IPP) and dimethylallyl pyrophosphate ( DMAPP) into isoprenoid lipids. These lipids, specifically geranylgeranyl pyrophosphate, are necessary for the post-translational prenylation of small GTPases such as RhoA and Rac1.

The absence of lipid modification prevents the small GTPases from anchoring to the cell membrane, effectively inactivating them. The resulting loss of GTPase function causes a rapid and targeted disruption of the actin cytoskeleton and ruffled border structure within bone-resorbing osteoclasts.

By suppressing osteoclast-mediated bone breakdown, the action of Novacor shifts the systemic bone remodeling balance, leading to a net preservation of mineralized bone matrix structure.

Advertisements

Dosage and Administration Information

Instruction Map: How to use Novacor — Official Administration Guidelines

Administration Scope

Entity Instruction
Route of administration Oral
Dosing schedule Hypertension / Angina: Start typically at 5 mg once daily; max 20 mg once daily. Stable Chronic Heart Failure: Begin at 1.25 mg once daily, with gradual uptitration to a max of 10 mg once daily.
Timing in relation to meals With or without food
Preparation requirements Swallow whole with liquid; do not chew.
Age-group administration rules Pediatric: Use is not recommended. Geriatric: May start at the lowest possible dose.
Missed-dose rules Take as soon as remembered, unless near the next dose; do not double the dose.
Special procedural conditions Renal/Hepatic Impairment: Dose should not exceed 10 mg once daily in severe cases. CHF: Must be initiated only in clinically stable patients.

Instruction Classifications (High-Level)

Classification Parameter
Administration method type Oral
Frequency pattern Once daily
Use-context constraints Long-term use; Gradual withdrawal required

Resulting Procedural Structure

Official step sequence:

  • Administration: The film-coated tablet is taken orally once daily, generally in the morning, and must be swallowed whole.
  • Initiation (CHF): Treatment for stable heart failure must commence at 1.25 mg and undergo a gradual uptitration in scheduled steps over a period of weeks to reach the target dose.
  • Maintenance: The dose is maintained daily within the established range (e.g., 5–10 mg for hypertension, 10 mg for CHF).
  • Discontinuation: If treatment must be stopped, the dose should be gradually reduced (tapered) over one to two weeks; abrupt cessation is strictly avoided.

Connection to the overall use protocol (2–4 sentences): The official use protocol establishes Novacor as an oral, once-daily medicine taken via an intact film-coated tablet, defining the singular route and frequency of its administration. The most critical procedural structure is the mandatory gradual dose adjustment at both the start and end of treatment, which dictates the time-course of the official regimen. The instructions clearly outline maximum doses based on the specific indication and specific limits for populations with organ impairment, setting strict parameters for use.

Advertisements

Recent Clinical Evidence

Novacor: Recent Clinical Evidence

Initial research explored the potential relationship between the Novacor combination and a reduction in chronic neuropathic pain. The focus of the evidence review is on trials that investigated the combination's influence on specific patient-reported outcomes.


Key Findings from Phase 3 Trials

A Phase 3, randomized, controlled trial (RCT) examined change in average daily pain scores, reporting a finding for the combination. The study's primary endpoint measured the change from baseline at week 12. The data observed a difference for the combination relative to both placebo and single-drug therapy.

The trial design did not include participants with pre-existing heart conditions. One study explored use of the combination in patients with refractory pain.


Investigation of Co-morbid Conditions

Preliminary data aimed to characterize the combination's influence on co-morbid anxiety in patients with neuropathic pain. Further evidence is needed to understand the scope and clinical significance of this observation.


Study Design and Safety Characterization

Study protocols investigated varied dosing schedules for the combination to determine the most appropriate regimen for trial participants. Long-term safety studies characterized the incidence of serious side effects. The studies also recorded the incidence of commonly observed adverse events, such as dry mouth and dizziness.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Novacor (FAQ)


Q: What is Novacor used for, in simple terms?

Official documents state that Novacor is used to help manage essential hypertension (high blood pressure) and chronic, stable angina pectoris (chest pain). It is also approved for the long-term treatment of stable chronic heart failure.


Q: Is Novacor a type of blood pressure medication?

Yes. The official indications for Novacor include the management of essential hypertension, which means it is classified as a medicine used to lower blood pressure.


Q: How quickly is Novacor expected to start working?

Regulatory information indicates that effects, such as a reduction in heart rate, can begin within a few hours after taking a dose. For blood pressure management, a reduction in pressure has been described in studies as commonly observed within one week of starting treatment.


Q: Do I have to take Novacor forever once I start it?

Treatment for chronic conditions like heart failure is generally described in official sources as long-term therapy. If a decision is made to stop the medicine, official guidance indicates that the dose should be gradually reduced over a period of time, as abrupt stopping is not recommended.


Q: What are the most common side effects of Novacor?

The official product information lists common side effects, occurring in 1% to 10% of patients in studies, as including fatigue, headache, dizziness, and stomach or intestinal issues like diarrhea or nausea.


Q: Can Novacor cause weight gain or weight loss?

Regulatory documents report that weight changes or weight gain have been noted as a potential adverse effect. Swelling, known as edema, particularly in the extremities, is also noted in the product information.


Q: Does Novacor interact with any common vitamins or supplements?

The product information specifically notes that co-administration with the herbal product St. John's Wort is associated with reduced drug levels in the body. The product information states that it is generally important to review all supplements with a healthcare provider.


Q: What happens if I stop taking Novacor suddenly?

Official warnings strongly advise against stopping treatment abruptly, especially for individuals with underlying heart conditions. Doing so may lead to a transitional worsening of heart condition, such as an exacerbation of chest pain.


Q: Is Novacor an anti-inflammatory drug?

No. Official documents classify Novacor pharmacologically as a beta-blocking agent, specifically a cardioselective beta-1 adrenoceptor antagonist. It is not classified as an anti-inflammatory medicine.


Q: How does Novacor differ from a beta-blocker?

Novacor is a beta-blocker. It is classified as a cardioselective beta1-adrenergic receptor blocking agent, meaning its primary action is to target specific receptors mainly located in the heart.


Q: Can Novacor affect my mood or cause anxiety?

Regulatory labels report potential effects on the central nervous system. These documented side effects include anxiety, depression, and sleep disturbances.


Q: Is there a generic version of Novacor available?

Yes. The active ingredient in Novacor, Bisoprolol fumarate, has been granted market authorization for generic versions in various international jurisdictions.


Q: Does Novacor require any special monitoring or regular blood tests?

Official guidance for initiating treatment in stable heart failure indicates the importance of close monitoring of vital signs (like heart rate and blood pressure). Also, the label notes that the drug can potentially mask symptoms of low blood sugar in people taking anti-diabetics.


Q: Is it safe to drive a car while taking Novacor?

The official product information warns that side effects such as dizziness or fatigue may occur, which could potentially impair the ability to drive or operate machinery. Regulatory labeling suggests that individuals should be aware of how the medicine affects them before operating a vehicle.


Q: Why is Novacor used to treat conditions X and Y?

Official indications list Novacor's use for treating essential hypertension (high blood pressure), chronic stable angina pectoris (chest pain), and managing stable chronic heart failure.


Q: Can Novacor be used by women who are pregnant or breastfeeding?

Official guidance states that use during pregnancy is only recommended if clearly needed. It also advises monitoring the newborn after birth. Use during breastfeeding is generally not recommended in some regions due to the potential for adverse effects in the infant.


Q: What is the active ingredient in Novacor?

The active substance in Novacor is Bisoprolol fumarate.


Q: How long does Novacor stay in your system after taking it?

The medicine is characterized by a half-life, which is the time it takes for half of the drug to be eliminated, of 9 to 12 hours in healthy individuals. It is intended for once-daily use.


Q: Do the side effects of Novacor usually go away over time?

Regulatory data indicates that many side effects are often described as mild and transient. However, specific common side effects, such as persistent fatigue, may continue for some individuals.


Q: Can Novacor affect fertility in men or women?

Official regulatory documents have reported adverse effects related to sexual function. These documented effects include reports of decreased libido and potency disorders.


Q: What is the difference between the different strengths of Novacor tablets?

The different strengths are intended for use during the initial dose titration phase and for the long-term maintenance dose. This allows for the gradual dose adjustment required for certain conditions, such as stable heart failure.


Q: Has Novacor been studied in children?

The official product information states that use in the pediatric population is generally not recommended. This is because the safety and effectiveness have not been definitively established in this age group through regulatory-cited studies.


Q: Is Novacor a prescription-only medicine?

Yes. Novacor (Bisoprolol fumarate) is regulated in most countries as a medicine that is available only by prescription from an authorized healthcare provider.


Q: Are there any known issues with taking Novacor before surgery?

Official warnings advise that the treatment should not be discontinued abruptly prior to major surgery. If treatment must be stopped, the dose should be gradually reduced.


Q: What should I look out for that indicates Novacor is working?

The medicine's intended effects, as described in official documents, include a reduction in resting heart rate and a lowering of blood pressure. These effects align with the goals of therapy for the approved conditions.


Q: Can I take Novacor if I have an existing heart condition?

Novacor is used to treat certain heart conditions, like stable heart failure. However, official sources list several heart conditions as contraindications (reasons not to use the drug), including cardiogenic shock, specific types of heart block, and very slow heart rate (marked bradycardia).


Q: What patient populations are generally excluded from using Novacor?

Official contraindications generally exclude patients with acute heart failure, specific types of severe heart block, and marked bradycardia (very slow heart rate). Caution is also advised in patients with severe obstructive airways diseases.


Q: Is Novacor commonly prescribed outside of [specific region]?

Yes, regulatory documents confirm that the drug is authorized for use in numerous major global markets, including the United States (FDA), Europe (EMA), and Canada (Health Canada).


Q: Are there different brand names for the drug Novacor?

Yes. Regulatory databases confirm that the active ingredient, Bisoprolol fumarate, is available under multiple brand names in addition to Novacor in different countries.


Q: What is the maximum duration for which Novacor is typically used?

For chronic conditions like stable heart failure, the treatment is generally considered long-term in official guidance. There is no specific maximum duration defined; the need for continued treatment is reviewed by a healthcare provider.


Q: Does Novacor have an official black box warning?

The U.S. FDA product label includes a prominent Warning section. This warning specifically advises against the abrupt cessation of therapy, as this can lead to serious cardiac events.


Q: Are there any known interactions between Novacor and herbal remedies?

The product information specifically notes an interaction with the herbal product St. John's Wort, which may reduce the drug's concentration in the body. Other interactions are not generally addressed in regulatory guidance.


Q: Can Novacor cause a rash or skin reactions?

Yes, official regulatory documents list various skin reactions as potential side effects. These documented effects include rash and pruritus (itching).


Q: Can people with asthma take Novacor?

Official product information advises that the drug should generally be avoided in patients with obstructive airways diseases, such as asthma. If its use is deemed necessary, regulatory guidance states it must be used with caution and at the lowest possible dose.


Q: Can Novacor be taken with common over-the-counter pain relievers?

Regulatory guidance includes a warning that combining Novacor with non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen) may reduce the blood-pressure lowering effect.


Q: Do you get withdrawal symptoms from stopping Novacor?

Abrupt cessation is officially warned against because it may lead to the transitional worsening of heart conditions (like exacerbation of chest pain). This is why the dose must be gradually tapered.


Q: Can Novacor cause problems with my stomach or digestion?

Yes, the product information lists common gastrointestinal adverse effects. These documented effects include nausea, vomiting, and diarrhea.


Q: Can Novacor affect my sleep?

Yes, regulatory documents list insomnia (difficulty sleeping) and other sleep disturbances, including vivid dreams, as reported side effects.


Q: Is dizziness a normal expected side effect of Novacor?

Yes, dizziness is listed in the official product information as one of the commonly reported adverse effects in clinical trials (occurring in 1% to 10% of patients).


Q: Can Novacor affect my heart rate?

Yes. The primary intended action of the drug is to produce a negative chronotropic effect, which results in a reduction in resting and exercise heart rate.


Q: What kind of research supports the use of Novacor?

Regulatory approval is supported by randomized, double-blind, placebo-controlled clinical trials. These studies demonstrated the drug's effectiveness in reducing blood pressure and, for heart failure, a significant reduction in mortality.


Q: Are the research findings for Novacor considered conclusive?

The regulatory authorization is based on clinical trials where the findings demonstrated a statistically significant clinical benefit. These data support the conclusion that the drug is effective and safe for its approved indications.


Advertisements

How should Novacor be stored and disposed of?

How to Store and Dispose of Novacor

Novacor (Bisoprolol fumarate) tablets must be stored according to regulatory requirements to ensure product quality and safety.

Requirement Storage Condition
Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F); do not store above 25 C.
Protection Store in the original container, protected from both light and moisture.
Child Safety Keep the medicine strictly out of the reach and sight of children.

The packaging must remain tightly closed. For certain large containers, regulatory documents specify that the product may have an in-use shelf-life limit, such as six months after opening. The disposal of unused or expired Novacor must adhere to local requirements and pharmacist guidance; the medicine should not be thrown into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Novacor found in:

A-Z Index: